A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hairmultiplicationtechnology are planned in partnership with Yinguan Biotechnology.
Han Bio plans to start clinical trials for a new hairmultiplicationtechnology this year, which could significantly reduce the cost and time of hair transplantation. The technology uses a single hair strand to cultivate enough cells for 30,000 hair strands.
Yunce Medical, a Chinese company, is developing hairmultiplicationtechnology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
HairClone plans to start hairmultiplication services in 2022. Users discuss various treatments like Minoxidil, finasteride, PRP, and hair cloning, expressing both hope and skepticism about the technology and its costs.
The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It also mentions ongoing human trials for hairmultiplication/cloning at Yokohama National University, with skepticism about the timeline.